Bristol Myers Squibb
Bristol Myers Squibb Company (NYSE: BMY) discovers, develops, licenses, manufactures, markets, distributes and sells prescription medicines for serious diseases, with research and commercial activity spanning oncology, hematology, immunology, cardiovascular disease and neuroscience. Its products include biologics,… From the company’s description.
In fiscal 2025, Bristol Myers Squibb reported revenue of $48.19B, down 0.2% from fiscal 2024, and net income of $7.05B. Its operating margin was 20.8%, and operations generated $14.16B in cash. Over the twelve months to Jun 30, 2026, revenue was $49.19B.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Bristol Myers Squibb does
In the company’s own words
Bristol Myers Squibb Company (NYSE: BMY) discovers, develops, licenses, manufactures, markets, distributes and sells prescription medicines for serious diseases, with research and commercial activity spanning oncology, hematology, immunology, cardiovascular disease and neuroscience. Its products include biologics, small-molecule drugs, antibody-drug conjugates, CAR-T cell therapies and radiopharmaceuticals; major brands include Opdivo, Eliquis, Orencia, Yervoy, Reblozyl, Breyanzi, Revlimid and Camzyos. The company operates as a single reportable segment. Its medicines are sold worldwide, principally to wholesalers, distributors and specialty pharmacies, as well as to retailers, hospitals, clinics, government agencies and, in some cases, patients; it also promotes products to healthcare professionals and organizations. Revenue was $48.2 billion for fiscal 2025, with 69% generated in the United States and 29% internationally. Bristol Myers Squibb traces its origins to a New York business established in 1887 and took its current name following a 1989 merger. Its website is www.bms.com.
Company details
- Sector
- Health Care
- Industry (SIC)
- Pharmaceutical Preparations
- Headquarters
- PRINCETON, NJ
- Fiscal year end
- December
- CIK
- 14272
- SIC
- 2834
Financial performance, year by year
Fiscal 2013–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Bristol Myers Squibb — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Superinvestors in Bristol Myers Squibb · what they did last quarter
Share of each manager’s reported 13F portfolio. Change is in shares held, since the previous quarter.
Largest fund holders · Bristol Myers Squibb’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Bristol Myers Squibb’s bonds, as funds hold them
Funds report holding 36 issues of Bristol Myers Squibb’s debt, $3.50B at market value — what funds hold, not the company’s total debt. Weighted-average coupon 4.34%, maturing 2026 to 2064.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Fund ownership is a subset of institutional 13F ownership — the two describe overlapping populations and must not be added together.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Bristol Myers Squibb and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Bristol Myers Squibb's earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Bristol Myers Squibb's last four quarterly filings that the numbers alone won't show?”